Provided by Tiger Trade Technology Pte. Ltd.

Allogene Therapeutics Inc.

1.69
-0.0300-1.74%
Post-market: 1.700.0124+0.73%19:56 EDT
Volume:5.65M
Turnover:9.68M
Market Cap:583.05M
PE:-2.60
High:1.77
Open:1.74
Low:1.66
Close:1.72
52wk High:4.46
52wk Low:1.04
Shares:345.00M
Float Shares:262.00M
Volume Ratio:1.03
T/O Rate:2.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6510
EPS(LYR):-0.8652
ROE:-42.39%
ROA:-22.08%
PB:1.34
PE(LYR):-1.95

Loading ...

Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma

THOMSON REUTERS
·
Jul 29

Allogene publishes Phase 1 data in Journal of Clinical Oncology

TIPRANKS
·
Jul 15

Allogene Says Phase 1 Trial Shows 31% Response Rate for Allo-316 in Cd70-high Metastatic Kidney Cancer

Reuters
·
Jul 15

Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of Allo-316 Highlighting First Durable Remissions Following Allogeneic Car T for Treatment of Metastatic Solid Tumors

THOMSON REUTERS
·
Jul 15

Allogene stockholders approve increase in authorized common shares to 800 million

Reuters
·
Jun 23

Press Release: Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

Dow Jones
·
Jun 11

Allogene names Zachary Roberts CEO, succeeding David Chang effective July 1, 2026

Reuters
·
May 29

Allogene Therapeutics - Appoints Zachary Roberts as President and CEO Effective July 1, 2026

THOMSON REUTERS
·
May 29

Allogene Therapeutics Announces Planned CEO Succession

THOMSON REUTERS
·
May 29

Allogene Therapeutics - David Chang to Transition From President and CEO, Will Remain on Board

THOMSON REUTERS
·
May 29

Allogene Therapeutics to present at TD Cowen Oncology Innovation Summit

Reuters
·
May 26

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Pharvaris (PHVS) and Allogene Therapeutics (ALLO)

TIPRANKS
·
May 14

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
May 14

Piper Sandler Sticks to Their Buy Rating for Allogene Therapeutics (ALLO)

TIPRANKS
·
May 14

Allogene Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 14

Allogene Therapeutics ends China cell therapy deal with Overland

Reuters
·
May 14

Allogene Therapeutics Q1 Net Loss Narrows

MT Newswires Live
·
May 14

BRIEF-Allogene Therapeutics - Enters Termination Agreement With Overland Therapeutics On May 12, 2026 - SEC Filing

Reuters
·
May 14

Allogene Therapeutics Inc - No Termination Payments Made in Connection With Termination Agreement - SEC Filing

THOMSON REUTERS
·
May 14

Allogene Therapeutics Inc - Terminates Exclusive License Agreement With Overland Therapeutics Effective May 12, 2026 - SEC Filing

THOMSON REUTERS
·
May 14